SCHEMBL2833210

SCHEMBL2833210

Cc1ccc(C(NC(=O)OC(C)(C)C)C(O)c2ccc(-c3cccnc3)cc2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
KDM4D Q6B0I6 1/20 0.40
PORCN Q9H237 1/20 0.38
SLC2A1 P11166 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
MKNK1 Q9BUB5 2/20 0.36
MKNK2 Q9HBH9 2/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
RAB9A P51151 1/20 0.36
ABCB1 P08183 4/20 0.36
ABCC1 P33527 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838260 0.89 TRPV1 (0.41) AKR1C3AKR1C2KDM4DAAK1
SCHEMBL2833102 0.89 KDM4D (0.42) KDM4DPORCNSLC2A1CYP19A1CYP11B1
SCHEMBL2833981 0.89 CYP3A4 (0.40) AKR1C3AKR1C2AAK1CYP17A1S1PR3
SCHEMBL2834769 0.81 ALDH1A1 (0.41) AKR1C3AKR1C2AAK1S1PR3
SCHEMBL2838698 0.80 CYP3A4 (0.36) CYP11B2AAK1S1PR3
SCHEMBL2832196 0.79 CYP11B2 (0.41) CYP11B1CYP11B2AAK1
SCHEMBL2834950 0.76 S1PR3 (0.40) CYP11B2AAK1S1PR3
SCHEMBL7813197 0.75 AKR1C3 (0.44) AKR1C3AKR1C2CYP19A1MKNK1MKNK2
SCHEMBL2841598 0.75 AKR1C3 (0.44) AKR1C3AKR1C2CYP19A1MKNK1MKNK2
SCHEMBL30759993 0.73 DHPS (0.47) KDM4DMKNK1MKNK2AAK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AKR1C3 1313/4885AKR1C2 924/4885KDM4D 2305/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AKR1C3 1313/4885AKR1C2 924/4885KDM4D 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.